| News & Announcements | Expiration of Coverage for Consumer Grade Pulse Oximeters Effective January 1, 2022 for Medicare Advantage Members | | | | | | 12/2/2021 | | | Expiration of Coverage for Consumer Grade Pulse Oximeters Effective January 1, 2022 for Medicare Advantage Members | |
| News & Announcements | Changes for COVID-19 Vaccination and Pharmaceutical Treatments for Medicare Advantage Members to Become Effective January 1, 2022 | | | | | | 12/7/2021 | | | Changes for COVID-19 Vaccination and Pharmaceutical Treatments for Medicare Advantage Members to Become Effective January 1, 2022 | |
| News & Announcements | Pharmaceutical Treatments of COVID-19 for Independence Medicare Advantage Members (Effective January 1, 2022) | | | | | | 12/31/2021 | | | Pharmaceutical Treatments of COVID-19 for Independence Medicare Advantage Members (Effective January 1, 2022) | |
| News & Announcements | Telehealth Services for Medicare Advantage Members | | | | | | 12/31/2021 | | | Telehealth Services for Medicare Advantage Members | |
| News & Announcements | Coverage of COVID-19 Vaccination for Medicare Advantage Members (Updated Effective January 1, 2022) | | | | | | 12/31/2021 | | | Coverage of COVID-19 Vaccination for Medicare Advantage Members (Updated Effective January 1, 2022) | |
| News & Announcements | Aduhelm™ (aducanumab-avwa) injection for Medicare Advantage Members (Updated January 1, 2022) | | | | | | 12/31/2021 | | | Aduhelm™ (aducanumab-avwa) injection for Medicare Advantage Members (Updated January 1, 2022) | |
| News & Announcements | 01/01/2022 CPT & HCPCS Quarterly Code Update Coverage Determinations for Medicare Advantage Products | | | | | | 12/31/2021 | | | 01/01/2022 CPT & HCPCS Quarterly Code Update Coverage Determinations for Medicare Advantage Products | |
| Notifications | eviCore Lab Management | MA06.034d | 12/1/2021 2:00 PM | 1/1/2022 | | | 12/1/2021 | Coverage and/or Reimbursement Position;Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | eviCore Lab Management | |
| Notifications | Electromyography (EMG) Studies: Needle EMG, Surface EMG (SEMG) | MA07.050i | 12/20/2021 12:00 PM | 3/21/2022 | | | 12/20/2021 | Coverage and/or Reimbursement Position;Medical Necessity Criteria | | Electromyography (EMG) Studies: Needle EMG, Surface EMG (SEMG) | |
| Notifications | Nerve Conduction Studies (NCS) and Related Electrodiagnostic Studies | MA07.033i | 12/20/2021 12:00 PM | 3/21/2022 | | | 12/20/2021 | Coverage and/or Reimbursement Position;Medical Necessity Criteria | | Nerve Conduction Studies (NCS) and Related Electrodiagnostic Studies | |
| Notifications | Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (Phesgo®) | MA08.129a | 12/21/2021 7:00 AM | 3/21/2022 | | | 12/21/2021 | Medical Necessity Criteria | | Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (Phesgo®) | |
| Notifications | Pegfilgrastim (Neulasta®) and Related Biosimilars | MA08.082h | 12/31/2021 9:00 AM | 4/1/2022 | | | 12/31/2021 | Coverage and/or Reimbursement Position | | Pegfilgrastim (Neulasta®) and Related Biosimilars | |
| Notifications | Rituximab (Rituxan®) Infusion and Related Biosimilars, and Rituximab/Hyaluronidase Human for Subcutaneous Injection (Rituxan Hycela®) | MA08.022n | 12/31/2021 9:00 AM | 4/1/2022 | | | 12/31/2021 | Coverage and/or Reimbursement Position | | Rituximab (Rituxan®) Infusion and Related Biosimilars, and Rituximab/Hyaluronidase Human for Subcutaneous Injection (Rituxan Hycela®) | |
| New Policies | Tisotumab vedotin-tftv (Tivdak™) | MA08.141 | | 12/20/2021 | | | 12/20/2021 | This is a New Policy. | | Tisotumab vedotin-tftv (Tivdak™) | |
| Updated Policies | Modifier 52: Reduced Services | MA03.014b | | 12/6/2021 | | | 12/6/2021 | General Description, Guidelines, or Informational Update | | Modifier 52: Reduced Services | |
| Updated Policies | Modifier 53: Discontinued Procedure | MA03.018b | | 12/6/2021 | | | 12/6/2021 | General Description, Guidelines, or Informational Update | | Modifier 53: Discontinued Procedure | |
| Updated Policies | Surgical and Minimally Invasive Treatments for Urinary Outlet Obstruction due to Benign Prostatic Hyperplasia (BPH) | MA11.004i | | 12/27/2020 | | | 12/6/2021 | Coverage and/or Reimbursement Position;Medical Necessity Criteria | | Surgical and Minimally Invasive Treatments for Urinary Outlet Obstruction due to Benign Prostatic Hyperplasia (BPH) | |
| Updated Policies | Carfilzomib (Kyprolis™) | MA08.062f | | 12/6/2021 | | | 12/6/2021 | Medical Necessity Criteria;Medical Coding | | Carfilzomib (Kyprolis™) | |
| Updated Policies | Ado-Trastuzumab Emtansine (Kadcyla®) | MA08.066e | | 12/6/2021 | | | 12/6/2021 | Medical Necessity Criteria;Medical Coding | | Ado-Trastuzumab Emtansine (Kadcyla®) | |
| Updated Policies | Sacituzumab govitecan-hziy (TrodelvyTM) | MA08.118c | | 12/6/2021 | | | 12/6/2021 | Medical Necessity Criteria;Medical Coding | | Sacituzumab govitecan-hziy (TrodelvyTM) | |
| Updated Policies | Enteral Nutritional Therapy | MA08.003f | | 12/6/2021 | | | 12/6/2021 | Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | Enteral Nutritional Therapy | |
| Updated Policies | Outpatient Physical Medicine and Rehabilitation Services- Physical Therapy (PT) and Occupational Therapy (OT) | MA10.003h | | 12/20/2021 | 12/20/2021 | | 12/20/2021 | Coverage and/or Reimbursement Position;Medical Necessity Criteria;Medical Coding | | Outpatient Physical Medicine and Rehabilitation Services- Physical Therapy (PT) and Occupational Therapy (OT) | |
| Updated Policies | Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)/(Abraxane® for Injectable Suspension) | MA08.049i | | 12/20/2021 | | | 12/20/2021 | Medical Necessity Criteria | | Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)/(Abraxane® for Injectable Suspension) | |
| Updated Policies | Pertuzumab (Perjeta®) | MA08.063e | | 12/20/2021 | | | 12/20/2021 | Medical Necessity Criteria;Medical Coding | | Pertuzumab (Perjeta®) | |
| Updated Policies | Wound Care: Skin Substitutes for the Treatment of Burns and Chronic, Non-Healing Wounds | MA11.015n | | 12/20/2021 | | | 12/20/2021 | General Description, Guidelines, or Informational Update | | Wound Care: Skin Substitutes for the Treatment of Burns and Chronic, Non-Healing Wounds | |
| Updated Policies | Infliximab and Related Biosimilars | MA08.019i | | 12/20/2021 | | | 12/20/2021 | Coverage and/or Reimbursement Position;Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | Infliximab and Related Biosimilars | |
| Updated Policies | Personalized Vaccines (e.g., Provenge®) | MA08.053b | | 12/20/2021 | | | 12/20/2021 | Medical Necessity Criteria | | Personalized Vaccines (e.g., Provenge®) | |
| Updated Policies | Enfortumab vedotin-ejfv (Padcev®) | MA08.113c | | 12/20/2021 | | | 12/20/2021 | Medical Necessity Criteria | | Enfortumab vedotin-ejfv (Padcev®) | |
| Updated Policies | Pain Management of Peripheral Nerves by Injection | MA07.047h | 9/27/2021 12:00 PM | 12/27/2021 | | | 12/27/2021 | Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | Pain Management of Peripheral Nerves by Injection | |
| Updated Policies | Dermabrasion for Rhinophyma, Septoplasty, Rhinoplasty, and Septorhinoplasty | MA11.099b | | 1/3/2022 | | | 12/31/2021 | Coverage and/or Reimbursement Position;Medical Coding;General Description, Guidelines, or Informational Update | | Dermabrasion for Rhinophyma, Septoplasty, Rhinoplasty, and Septorhinoplasty | |
| Updated Policies | Intraoperative Neurophysiological Testing | MA07.051h | | 1/3/2022 | | | 12/31/2021 | Coverage and/or Reimbursement Position;General Description, Guidelines, or Informational Update | | Intraoperative Neurophysiological Testing | |
| Updated Policies | eviCore Lab Management | MA06.034d | 12/1/2021 2:00 PM | 1/1/2022 | | | 12/31/2021 | Coverage and/or Reimbursement Position;Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | eviCore Lab Management | |
| Updated Policies | National Correct Coding Initiative (NCCI) Code Pair Edits | MA00.041a | | 1/3/2022 | | | 12/31/2021 | Medical Coding;General Description, Guidelines, or Informational Update | | National Correct Coding Initiative (NCCI) Code Pair Edits | |
| Updated Policies | Reporting and Documentation Requirements for Anesthesia Services | MA00.009h | | 1/1/2022 | | | 12/31/2021 | General Description, Guidelines, or Informational Update | | Reporting and Documentation Requirements for Anesthesia Services | |
| Reissue Policies | Cobalamin (Vitamin B12), Folic Acid, and Homocysteine Testing | MA06.032 | | 5/28/2019 | 11/17/2021 | | 12/15/2021 | | | Cobalamin (Vitamin B12), Folic Acid, and Homocysteine Testing | |
| Reissue Policies | Upper Gastrointestinal Endoscopy (Diagnostic and Therapeutic) | MA07.023g | | 10/1/2021 | 11/17/2021 | | 12/15/2021 | | | Upper Gastrointestinal Endoscopy (Diagnostic and Therapeutic) | |
| Reissue Policies | Patisiran (Onpattro™) | MA08.100b | | 10/1/2019 | 11/17/2021 | | 12/15/2021 | | | Patisiran (Onpattro™) | |
| Reissue Policies | Nusinersen (Spinraza®) | MA08.086d | | 12/17/2018 | 11/17/2021 | | 12/15/2021 | | | Nusinersen (Spinraza®) | |
| Reissue Policies | Measurement of Exhaled Nitric Oxide and Breath Condensate in the Diagnosis and Management of Asthma and Other Respiratory Disorders | MA07.044b | | 3/26/2018 | 11/17/2021 | | 12/15/2021 | | | Measurement of Exhaled Nitric Oxide and Breath Condensate in the Diagnosis and Management of Asthma and Other Respiratory Disorders | |
| Coding Update | Pulmonary Rehabilitation Services | MA10.001b | | 1/1/2022 | 1/1/2022 | | 12/31/2021 | | | Pulmonary Rehabilitation Services | |
| Coding Update | Musculoskeletal Services | MA00.047e | | 1/1/2022 | 1/1/2022 | | 12/31/2021 | | | Musculoskeletal Services | |
| Coding Update | Ambulatory Electrocardiography (AECG) Monitoring and Mobile Cardiac Outpatient Telemetry (MCOT) Monitoring | MA07.026h | | 1/1/2022 | 1/1/2022 | | 12/31/2021 | | | Ambulatory Electrocardiography (AECG) Monitoring and Mobile Cardiac Outpatient Telemetry (MCOT) Monitoring | |
| Coding Update | Catheter Ablation of Cardiac Arrhythmias | MA11.060d | | 1/1/2022 | 1/1/2022 | | 12/31/2021 | | | Catheter Ablation of Cardiac Arrhythmias | |
| Coding Update | Endovascular Stent-Graft Repair of Thoracic Aortic Aneurysms and Nonaneurysmal Lesions | MA11.062a | | 1/1/2022 | 1/1/2022 | | 12/31/2021 | | | Endovascular Stent-Graft Repair of Thoracic Aortic Aneurysms and Nonaneurysmal Lesions | |
| Coding Update | Medicare Part B vs. Part D Crossover Drugs | MA08.007z | | 1/1/2022 | 1/1/2022 | | 12/31/2021 | | | Medicare Part B vs. Part D Crossover Drugs | |
| Coding Update | Capsule Endoscopy | MA07.022d | | 1/1/2022 | 1/1/2022 | | 12/31/2021 | | | Capsule Endoscopy | |
| Coding Update | High-Technology Radiology Services | MA09.002t | | 1/1/2022 | | | 12/31/2021 | | | High-Technology Radiology Services | |
| Coding Update | pegfilgrastim (Neulasta®) and related biosimilars | MA08.082f | | 1/1/2022 | | | 12/31/2021 | | | pegfilgrastim (Neulasta®) and related biosimilars | |
| Coding Update | Chimeric Antigen Receptor (CAR) Therapy | MA08.093j | | 1/1/2022 | | | 12/31/2021 | | | Chimeric Antigen Receptor (CAR) Therapy | |
| Coding Update | Autonomic Nervous System Testing | MA07.027e | | 1/1/2022 | | | 12/31/2021 | | | Autonomic Nervous System Testing | |
| Coding Update | Cataract Surgery | MA11.054d | | 1/1/2022 | | | 12/31/2021 | | | Cataract Surgery | |
| Coding Update | Sacral Nerve Stimulation (SNS) and Posterior Tibial Nerve Stimulation (PTNS) for the Control of Incontinence | MA11.028g | | 1/1/2022 | | | 12/31/2021 | | | Sacral Nerve Stimulation (SNS) and Posterior Tibial Nerve Stimulation (PTNS) for the Control of Incontinence | |
| Coding Update | Endovascular Grafts for Abdominal Aortic Aneurysms, Aortic-Iliac Aneurysms, and Infrarenal Aortic Aneurysms | MA11.012f | | 1/1/2022 | | | 12/31/2021 | | | Endovascular Grafts for Abdominal Aortic Aneurysms, Aortic-Iliac Aneurysms, and Infrarenal Aortic Aneurysms | |
| Coding Update | Vagus Nerve Stimulation (VNS) | MA11.019g | | 1/1/2022 | | | 12/31/2021 | | | Vagus Nerve Stimulation (VNS) | |
| Coding Update | Aqueous Shunts, Microstents, Viscocanalostomy, and Canaloplasty for the Treatment of Glaucoma | MA11.105h | | 1/1/2022 | | | 12/31/2021 | | | Aqueous Shunts, Microstents, Viscocanalostomy, and Canaloplasty for the Treatment of Glaucoma | |
| Coding Update | Extracorporeal Shock Wave Therapy (ESWT) for Musculoskeletal Conditions | MA11.087c | | 1/1/2022 | | | 12/31/2021 | | | Extracorporeal Shock Wave Therapy (ESWT) for Musculoskeletal Conditions | |
| Coding Update | Platelet-Rich Plasma (PRPs) for Chronic Non-Healing Wounds and Stem-Cell Therapy for Orthopedic Applications | MA07.008c | | 1/1/2022 | | | 12/31/2021 | | | Platelet-Rich Plasma (PRPs) for Chronic Non-Healing Wounds and Stem-Cell Therapy for Orthopedic Applications | |
| Coding Update | Noninvasive Techniques for the Evaluation and Monitoring of Individuals with Chronic Liver Disease | MA06.024e | | 1/1/2022 | | | 12/31/2021 | | | Noninvasive Techniques for the Evaluation and Monitoring of Individuals with Chronic Liver Disease | |
| Archived Policies | Melphalan flufenamide (Pepaxto®) | MA08.135b | 12/1/2021 3:00 PM | 1/1/2022 | | | 12/1/2021 | | | Melphalan flufenamide (Pepaxto®) | |
| Archived Policies | Ibalizumab-uiyk (Trogarzo™) | MA08.096a | 12/3/2021 1:00 PM | 1/3/2022 | | | 12/3/2021 | | | Ibalizumab-uiyk (Trogarzo™) | |
| Archived Policies | Tagraxofusp-erzs (Elzonris®) | MA08.105c | 12/3/2021 2:00 PM | 1/3/2022 | | | 12/3/2021 | | | Tagraxofusp-erzs (Elzonris®) | |